Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
B2611002 is designed to study how safe and effective an investigational medication
(PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 5
treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug,
and another treatment will be placebo, which does not contain active ingredient.